Sharapova Doping No Boost for Latvian Drugmaker, Swedbank Says

  • Grindeks' shares trading near lowest level since 2009
  • Company's sales in Russian market dropped 51% last year
Photographer: Ture Lillegraven/Bloomberg Pursuits

Latvian pharmaceutical company Grindeks AS traded near a six-year low as investors speculated the publicity surrounding tennis star Maria Sharapova’s admission she used its banned Mildronate brand won’t offset slumping sales in Russia.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.